| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
2-Cyclopentenone has been reported to inhibit the activity of HepG2 cells and has inhibitory activity against urease in Sporosarcina pasteurii. It also acts as an Hsp70 inducer and can inhibit LPS-induced ERK 1/2 activation. It is both an enone and an alicyclic ketone.
|
|---|---|
| ln Vitro |
In vitro, 2-cyclopentenone can inhibit the activity of HepG2 cells, suggesting potential antiproliferative effects. It also exhibits inhibitory activity against urease from Sporosarcina pasteurii. Its research value is paramount in the synthesis of natural products, including prostaglandins and other bioactive cyclopentanoids.
|
| ln Vivo |
In vivo data for 2-cyclopentenone as a therapeutic agent are not extensively documented. It is primarily used as a biochemical reagent and synthetic intermediate. Its role as an Hsp70 inducer suggests potential for in vivo studies in models of cellular stress and neuroprotection.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, 2-cyclopentenone can be evaluated for urease inhibitory activity. Standard protocols involve incubating the compound with urease from Sporosarcina pasteurii and measuring the amount of ammonia produced using a colorimetric assay. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based experiments, 2-cyclopentenone is evaluated for its effects on cell viability. Cells such as HepG2 are seeded in 96-well plates and treated with the compound at various concentrations for 24-72 hours. Cell viability is assessed using MTT or resazurin-based assays. The compound's ability to inhibit cell viability is quantified.
|
| Animal Protocol |
In vivo animal studies using 2-cyclopentenone are limited. For potential Hsp70 inducer candidates, efficacy studies would typically be performed in mouse models of neurodegenerative diseases. Standard in vivo protocols involve administration to rodents via intraperitoneal injection, with measurement of Hsp70 levels and assessment of neuroprotective effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-cyclopentenone as a standalone compound are not characterized in the literature. The compound has a molecular weight of 82.1 g/mol and is soluble in DMSO. In vivo formulation may involve 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline.
|
| Toxicity/Toxicokinetics |
2-Cyclopentenone is a research chemical and should be handled with appropriate laboratory safety precautions. As a cyclic enone, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
2-Cyclopenten-1-one is an enone with the structure cyclopentanone, possessing a C=C double bond at the 2-position. It can act as an Hsp70 inducer. It is both an enone and an alicyclic ketone. It has been reported that perilla contains 2-cyclopenten-1-one, and relevant data are available.
2-Cyclopentenone (Cyclopent-2-enone) (CAS 930-30-3) is primarily a research-grade chemical intermediate and biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are in the synthesis of natural products and bioactive cyclopentanoids and as a sulfonylation reagent for organic synthesis and drug discovery. |
| Molecular Formula |
C5H6O
|
|---|---|
| Molecular Weight |
82.10
|
| Exact Mass |
82.041
|
| CAS # |
930-30-3
|
| PubChem CID |
13588
|
| Appearance |
Colorless to light yellow liquid（Density：1.004 g/cm³）
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
136.0±0.0 °C at 760 mmHg
|
| Flash Point |
42.2±0.0 °C
|
| Vapour Pressure |
7.5±0.2 mmHg at 25°C
|
| Index of Refraction |
1.492
|
| LogP |
-0.05
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
6
|
| Complexity |
92.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1CCC=C1
|
| InChi Key |
BZKFMUIJRXWWQK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H6O/c6-5-3-1-2-4-5/h1,3H,2,4H2
|
| Chemical Name |
cyclopent-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (1218.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (30.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (30.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (30.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 12.1803 mL | 60.9013 mL | 121.8027 mL | |
| 5 mM | 2.4361 mL | 12.1803 mL | 24.3605 mL | |
| 10 mM | 1.2180 mL | 6.0901 mL | 12.1803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
